Opportunity
Federal Register #2026-21358
DEA Controlled-Substance Registration Applications for Manufacturing and Importing
Buyer
Justice Department / Drug Enforcement Administration
Posted
October 19, 2026
Respond By
November 18, 2026
Identifier
2026-21358
The Department of Justice’s Drug Enforcement Administration published controlled-substance registration application notices; this is a regulatory notice, not a procurement solicitation. - Government agency: U.S. Department of Justice, Drug Enforcement Administration (DEA); no specific office is identified. - Applicants and organizations named: - Groff Health Inc seeks bulk-manufacturer registration for ibogaine, 3,4-methylenedioxymethamphetamine, psilocybin, and psilocyn, for internal use and customer sales. - National Center for Natural Products Research seeks importer registration for marihuana and tetrahydrocannabinols to obtain genetic materials with different cannabinoid profiles for research and manufacturing. - DMS Pharmaceutical Group seeks importer registration for fentanyl for distribution to military combat units. - Groff NA Hemplex LLC is mentioned, but the notice excerpt provides no substance details for its application. - Substances and listed drug codes: ibogaine (7260), 3,4-methylenedioxymethamphetamine (7405), psilocybin (7437), psilocyn (7438), marihuana (7360), tetrahydrocannabinols (7370), and fentanyl (9801). Quantities are not specified. - The National Center for Natural Products Research application is limited to importing the listed substances for the described research and manufacturing purpose; it does not authorize importing finished dosage forms for commercial sale.
Description
The National Center for Natural Products Research applied to the Drug Enforcement Administration to register as an importer of marihuana and tetrahydrocannabinols. The center plans to acquire new genetic materials with different cannabinoid profiles for research and manufacturing purposes. No other activities for these drug codes are authorized under the registration, and authorization does not extend to importing finished dosage forms for commercial sale. Comments or objections and requests for a hearing are due by November 18, 2026.